搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Tissue-type Plasiminogen Actilyse,t-PA ELISA Kit

Human Tissue-type Plasiminogen Actilyse,t-PA ELISA Kit

  • 中文名稱：
    人組織型纖溶酶原激活劑(t-PA)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-E07916h
  • 規(guī)格：
    96T/48T
  • 價格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人組織型纖溶酶原激活劑(t-PA)酶聯(lián)免疫試劑盒（CSB-E07916h）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、組織勻漿.樣本中的PLAT含量。PLAT即組織型纖溶酶原激活劑，是一種絲氨酸蛋白酶。它在體內(nèi)參與纖維蛋白溶解過程，可特異性激活纖溶酶原轉(zhuǎn)化為纖溶酶，以溶解血栓。其研究機(jī)制聚焦于激活機(jī)制、與抑制劑互作，在血栓性疾病治療上有重要研究價值。試劑盒檢測范圍為0.156 ng/ml-10 ng/ml，靈敏度為0.039 ng/ml。適用于體外研究場景，如藥物開發(fā)中溶栓藥物效價評估、心血管疾病模型中的纖溶功能研究，或組織工程中t-PA調(diào)控機(jī)制的探索，為科研人員提供標(biāo)準(zhǔn)化、高重復(fù)性的檢測方案。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名：
    Alteplase ELISA Kit; DKFZp686I03148 ELISA Kit; Plasminogen activator tissue ELISA Kit; Plasminogen activator tissue type ELISA Kit; PLAT ELISA Kit; Reteplase ELISA Kit; t PA ELISA Kit; T Plasminogen Activator ELISA Kit; t-PA ELISA Kit; T-plasminogen activator ELISA Kit; Tissue plasminogen activator (t PA) ELISA Kit; Tissue type plasminogen activator ELISA Kit; Tissue-type plasminogen activator chain B ELISA Kit; tPA ELISA Kit; TPA_HUMAN ELISA Kit; TPA1 ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates
  • 檢測范圍：
    0.156 ng/ml-10 ng/ml
  • 靈敏度：
    0.039 ng/ml
  • 反應(yīng)時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Cardiovascular
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：

    Intra-assay Precision (Precision within an assay): CV%<8%

    Three samples of known concentration were tested twenty times on one plate to assess.

    Inter-assay Precision (Precision between assays): CV%<10%

    Three samples of known concentration were tested in twenty assays to assess.

    　

    Intra-Assay Precision

    Inter-Assay Precision

    Sample

    1

    2

    3

    1

    2

    3

    n

    20

    20

    20

    20

    20

    20

    Mean(ng/ml)

    1.354

    1.272

    1.216

    1.108

    1.241

    1.297

    SD

    0.034

    0.033

    0.026

    0.034

    0.043

    0.046

    CV(%)

    3.728

    3.767

    3.055

    4.245

    4.988

    5.186

  • 線性度：

    To assess the linearity of the assay, samples were spiked with high concentrations of human t-PA in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

    　

    Sample

    Serum(n=4)

    1:1

    Average %

    88

    Range %

    84-92

    1:2

    Average %

    94

    Range %

    90-98

    1:4

    Average %

    99

    Range %

    95-104

    1:8

    Average %

    102

    Range %

    96-108

  • 回收率：

    The recovery of human t-PA spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

    Sample Type

    Average % Recovery

    Range

    Serum (n=5)

    89

    83-96

    EDTA plasma (n=4)

    100

    95-105

  • 標(biāo)準(zhǔn)曲線：

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

    ng/ml

    OD1

    OD2

    Average

    Corrected

    10

    2.264

    2.298

    2.281

    2.134

    5

    1.841

    1.869

    1.855

    1.708

    2.5

    1.274

    1.297

    1.286

    1.139

    1.25

    0.862

    0.897

    0.880

    0.733

    0.625

    0.597

    0.574

    0.586

    0.439

    0.313

    0.415

    0.439

    0.427

    0.280

    0.156

    0.251

    0.272

    0.262

    0.115

    0

    0.146

    0.148

    0.147

    　

  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價

靶點(diǎn)詳情

  • 最新研究進(jìn)展：
    PLAT，全稱為組織型纖溶酶原激活劑（tissue-type plasminogen activator），是一種酶類蛋白質(zhì)，具有促進(jìn)纖溶作用的功能。最近的研究表明，PLAT在多種疾病中扮演著重要角色，包括血栓性疾病和癌癥等。一些研究已經(jīng)探索了PLAT的抑制劑和抗體，以期望發(fā)現(xiàn)更有效的治療方案。
  • 功能：
    Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. During oocyte activation, plays a role in cortical granule reaction in the zona reaction, which contributes to the block to polyspermy.
  • 基因功能參考文獻(xiàn)：
    1. These findings provides evidence that gene-gene interactions between p11, tPA and BDNF are all associated with post stroke depression. PMID: 29028593
    2. Underexpression of Tissue plasminogen activator is associated with diabetic foot syndrome. PMID: 28193577
    3. By mediating the tPA response in macrophages, the NMDA-R provides a pathway by which the fibrinolysis system may regulate innate immunity. PMID: 28684538
    4. Data suggest that protein aggregates interact with tissue-type plasminogen activator and plasminogen to efficiently generate plasmin; this aggregate-bound plasmin is shielded from inhibition by alpha-2-antiplasmin and degrades protein aggregates to release smaller, soluble but relatively hydrophobic peptide fragments; these fragments bind to and are cytotoxic to microglia (by not vascular endothelial cells). PMID: 28710283
    5. Altogether, this preclinical study demonstrates that the tPA present in the blood stream is a key player of the formation of intracranial aneurysms. PMID: 28754830
    6. tPA is a ligand of the N-terminal domain of the obligatory GluN1 subunit of NMDAR acting as a modulator of their dynamic distribution at the neuronal surface and subsequent signaling. PMID: 27831563
    7. t-PA binds to Lys91 in the MBP NH2-terminal region and PLGbinds to Lys122 in the MBP COOH-terminal region. This proximity promotes the activation of Pg by t-PA. PMID: 28648598
    8. local accumulation of cortisol is a causative factor for amnion epithelial apoptosis via activation of tPA/plasmin system toward the end of gestation. This may contribute to the ROM at both term and preterm birth. PMID: 27690691
    9. We identified a homozygous null mutation in PLAT that abrogated t-PA level in patient cells. This is the first reported human knockout mutation of PLAT. The apparent association with hydranencephaly, diaphragmatic hernia and postnatal lethality requires further validation. PMID: 27417437
    10. Tissue plasminogen activator (t-PA) antigen is a marker of cardiovascular risk. Exercise interventions associated with weight loss reduce t-PA antigen. Endurance training per se reduces t-PA antigen in healthy overweight men. PMID: 28254694
    11. we reviewed current knowledge of mechanisms by which tPA can influence brain function in physiological and pathological conditions--REVIEW} PMID: 26626577
    12. Data suggest that baseline levels of adiponectin, C-reactive protein, TPA, and fibrinogen or changes in these levels do not explain increased risk of diabetes type 2 in overweight women with glucose intolerance and histories of gestational diabetes. PMID: 25970741
    13. Tissue plasminogen activator (tPA) may be a general factor in the immunological response to viruses. PMID: 26704613
    14. tPA has a role in progression of periventricular white matter hyperintensities PMID: 26942412
    15. These data indicate that oxygen-glucose deprivation-triggered Cav-1 S-nitrosylation interacts with tPA-induced ERK activation to augment MMP2 and 9 secretion and subsequent extracellular matrix degradation. PMID: 26881424
    16. tPA-dependent activation of EGFRs leads to downregulation of NMDAR signaling and to subsequent neurotrophic effects. PMID: 26469972
    17. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalization may improve safety of thrombolytic therapy. PMID: 25855589
    18. Intravenous tissue plasminogen activator therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged>80 years) with acute ischemic stroke. PMID: 25329379
    19. Review: t-PA function and regulation of its pericellular activity, with an emphasis on regulation of its gene expression. PMID: 24718307
    20. data implicate MCP-1 as the key molecule governing tPA-induced fluid accumulation. The role of MCP-1 in the development of other exudative effusions warrants examination. PMID: 25474480
    21. remarkable association especially between the -1131C Apo A5 variant and increased tPA levels in asymptomatic dyslipidemic patients PMID: 24815086
    22. The results suggest roles for TLR3, TLR10, PLAT (n=2), VEGFA and DENND1B in susceptibility to chronic cavitary pulmonary aspergillosis. PMID: 24712925
    23. shRNA-mediated silencing of PLAT in glioma-initiating cells phenocopied the effects of miR340 overexpression in vitro effects of miR340 overexpression in vitro PMID: 25627976
    24. Activation of T cells triggered a rapid, 8.4-fold up-regulation of the serine protease tissue plasminogen activator, the protease target for neuroserpin. PMID: 25670787
    25. Report tPA with a cutoff of 8.5 ng/mL has a high sensitivity and negative predictive value for exclusion of pulmonary embolism. PMID: 25339163
    26. Data indicate that binding of tissue-type plasminogen activator (t-PA) to glucose-regulated protein 78 (GRP78) stimulates its amidolytic activity, activation of plasminogen (Pg), and cell proliferation. PMID: 25059665
    27. Obese men exhibited lower levels of TPA activity compared to normal weight men. PMID: 25306554
    28. plasminogen and plasmin but not tissue-type plasminogen activator have roles in regulating fibrinolysis by C-terminal lysines PMID: 22974122
    29. It is involved in Amyloid-beta catabolism and clearance, which is particularly efficient for degrading Amyloid-beta aggregates. Thus, endogenous tPA could delay Alzheimer's disease pathogenesis by maintaining low levels of brain Amyloid beta. PMID: 24126163
    30. Data suggest that tPA is required for bone repair and osteoblast proliferation; recombinant tPA stimulates proliferation of osteoblastic cell line. PMID: 24918201
    31. Endogenously released tPA promotes neutrophil transmigration to reperfused tissue via proteolytic activation of plasmin and gelatinases. PMID: 24764453
    32. There are correlations between t-PA, PAI-1 and some rotational thromboelastometry parameters in multiple myeloma patients. PMID: 24964508
    33. Identify 3 loci associated with circulating tPA levels, the PLAT region, STXBP5, and STX2. Functional studies implicate a novel role for STXBP5 and STX2 in regulating tPA release. PMID: 24578379
    34. Studies suggest that inadequate synthesis and release of tissue plasminogen activator (tPA) or low tPA activity be considered a critical component of schizophrenia pathophysiology. PMID: 24108470
    35. Tissue plasminogen activator (t-PA) is a model of preterm intracerebral-intraventricular hemorrhages for the ontogenic window of vascular immaturity and protection against later neurodisabilities. PMID: 24709679
    36. Data suggest plasma tissue plasminogen activator (t-PA) and fibrin fragment D-dimer levels are higher in abdominal aortic aneurysm patients than in controls; however, there is a negative relationship between t-PA and intraluminal thrombus thickness. PMID: 23959729
    37. LRP1 assembles unique co-receptor systems to initiate cell signaling in response to tissue-type plasminogen activator and myelin-associated glycoprotein. PMID: 24129569
    38. Renal impairment is associated with higher risk of symptomatic intracranial hemorrhage (sICH) after administration of intravenous tPA. PMID: 24145699
    39. Successful thrombolysis can resolve DWI lesions but does not always improve the neurological symptoms. PMID: 21848677
    40. Excess tissue-type plasminogen activator causes targeted Purkinje cell degeneration and ataxia. PMID: 23939410
    41. II genotype carrier osteomyelitis patients had lower PAI-1/tPA complex levels. PMID: 23570848
    42. Intravenous thrombolysis with alteplase does not appear to increase the risk of hemorrhagic complications in these non-metastatic cancer patients, in absence of additional risk factors of bleeding. PMID: 23317922
    43. The combination of recombinant PA and erythropoietin increases release of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) and thereby potentially deteriorates ischemic stroke outcome. PMID: 23788583
    44. Use of intraventricular tPA for aneurysmal subarachnoid hemorrhage surgery results in less vasospasm, fewer angioplasties, and fewer cerebrospinal fluid shunting procedures. PMID: 20559098
    45. Persons who develop non-affective psychoses have lower levels of certain acute phase proteins, including tPA, at the time of birth. PMID: 23423137
    46. This meta-analysis suggested that the -7351C/T polymorphism in TPA gene would be a risk factor for ischemic stroke. PMID: 23326456
    47. These results suggest that retained tPA on vascular endothelial cells effectively activated plasminogen to plasmin. PMID: 23118500
    48. The serine protease tissue plasminogen activator (tPA) and two matrix metalloproteinases, ADAMTS-4 and ADAMTS-5, were identified as Reelin cleaving enzymes. PMID: 23082219
    49. Intraventricular fibrinolysis with recombinant tPA does not lead to increased perihemorrhagic edema after intracerebral hemorrhage. PMID: 23306318
    50. VDAC binds tissue-type plasminogen activator (t-PA) on human neuroblastoma SK-N-SH cells PMID: 23161549

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism.
  • 亞細(xì)胞定位：
    Secreted, extracellular space.
  • 蛋白家族：
    Peptidase S1 family
  • 組織特異性：
    Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 9051

    OMIM: 173370

    KEGG: hsa:5327

    STRING: 9606.ENSP00000220809

    UniGene: Hs.491582